DEPREDONE

Main information

  • Trade name:
  • VR DEPREDONE INJECTION OF LONG ACTING PREDNISOLONE FOR DOGS, CATS AND HORSES
  • Available from:
  • VR
  • Pharmaceutical form:
  • PARENTERAL LIQUID/SOLUTION/SUSPENSION
  • Units in package:
  • 10mL
  • Class:
  • Veterinary Medicine
  • Medicine domain:
  • Animals
  • Medicine type:
  • Allopathic drug
  • Manufactured by:
  • AUSRICHTER

Documents

Localization

  • Available in:
  • VR DEPREDONE INJECTION OF LONG ACTING PREDNISOLONE FOR DOGS, CATS AND HORSES
    Australia
  • Language:
  • English

Therapeutic information

  • Therapeutic group:
  • CAT | DOG | HORSE | BITCH | CASTRATE | CAT - QUEEN | CAT - TOM | COLT | DONKEY | ENDURANCE HORSE | FILLY | FOAL | GELDING | HIGH
  • Therapeutic area:
  • corticosteroid
  • Therapeutic indications:
  • ANTI-INFLAMMATORY AGENT | ARTHRITIS | DERMATITIS | EOSINOPHILIC GRANULOMAS | MUSCULOSKELETAL CONDITIONS | OCULAR CONDITION | PRURITIS | ALLERGIC SKIN DISORDER | ANTIPYRETIC | ARTHRITIS | ARTHROSIS | BONE SORENESS | BRUISING | BURSITIS | EXTERNAL MYOPATHY | GANGRENOUS | INFLAMATION OF SOFT TISSUES AN | INFLAMMATORY RHEUMATIC ARTHRIT | JOINT DISEASE | LIGAMENT SPRAINS | MUSCLE SORENESS | OSTEITIS | OSTEOARTHRITIS | PLATELET ACTIVITY | RHEUMATISM | SKIN DISORDER | SPRAINS | STRAINS | TENDON AND LIGAMENT SPRAINS | TENDON SPRAINS | TENDONITIS | TENOSYNOVITIS | TRAUMATIC JOINT AND CONNECTIVE | TRAUMATIC SWELLING
  • Product summary:
  • Suppression of inflammation, arthritic conditions, relief of pruritis and inflammation in dermatitis in dogs, cats and horses. Allergic conditions in dogs and cats, Pain and lameness associated with musculoskeletal conditions, and ocular conditions.Do not use in ulcerative conditions of the cornea (until a negative fluorescein stain has been obtained) or in animals with Cushing’s Disease. See also PRECAUTIONS/ADVERSE REACTIONS on leaflet.

Other information

Status

  • Source:
  • Australian Pesticides and Veterinary Medicines Authority (APVMA)
  • Authorization status:
  • Registered but not available
  • Authorization number:
  • 36216/01
  • Authorization date:
  • 30-08-1996
  • Last update:
  • 15-06-2017

Patient Information leaflet: composition, indications, side effects, dosage, interactions, adverse reactions, pregnancy, lactation

PRESCRIPTION ANIMAL REMEDY

KEEP OUT OF REACH OF CHILDREN

FOR ANIMAL TREATMENT ONLY

BBU

DEPREDONE@

INJECTION OF LONG-ACTING

PREONISOLONE

FOR DOGS,

CIWS

AND HORSES

COMPOSITION: Methylpredmsolone acetate 40

mg/mL

(equrvalent to 34.6

mg/mL

methylprednisolone); benzyl alcohol 1

ml-/100

mL as preservative.

ACTIONS:

Prolonged

action

synthetic

anti-mflammatoj

sterord

wrth

mmlmal

mrneralocortrcord activity. In this depot form, the sterord

slowly released and has

a therapeutic duration of 2 to 3 weeks.

INDICATIONS: Suppression of mflammatron. arthritic condihons: relief of pruritisand

mflammation

in dermatitis in dogs, cats and horses.

A//erg/c conditions in dogs and

cats Pruritis

associated

with

contact

allergens

Systemic allergic conditions are more effective!y treated with an intravenous steroid

such as dexamethasone.

Musculoskeletal

conditions. Pain and lameness associated with local or systemic

nonseptic arthrrtrc conditions; also of benefit

the management of acuteand chrome

synovitrs,

tendomtis,

bursrtrs, myositis and periostitis. The drug may be administered

topically (into the lesion) or systemically.

Ocular

conditions.

Management

inflammatory

conditions.

Subconjunctival

administration of the drug results

a high concentration of the drug and a prolonged

duration of therapy

the eye, thus avoiding the frequent administration of steroids

that are required wrth other therapeutic preparations

‘fosmophlc

gfanulomas

m

cats.'

These

have also been successfully treated by the

systemic use of Depredone However, a more beneficial regimen has been observed

by the intralesronal injection of triamcinolone acetonide.

PRECAUTIONS: Corticosterords tend to decrease chemotachc properties of phagocytes

and thus tend to decrease the efficacy of host defence mechanisms They may also

tend to modrfy the natural antibody defence mechanisms.

Use with caution where severe tissue damage is present It is recommended that

such cases and where an infective process

suspected, antibiotic therapy should also

be used.

Avoid repeated

rntra-articular

Injection.

The oral or parenteral administration of

corbcosteroids

has been demonstrated !o

precrprtate premature parturrtion during the last trimester of pregnancy

ADVERSE REACTIONS: The relief afforded by the

anti-rnflammatory

response may

result

the animal using the affected part and

inflrchng further damage to

anrmai

should

therefore,

?aken

out of work for the duration

nf ‘he theraoeutrc

orogramme

!r;tra-articular

steroid

administration

result

degeneratinn rjf the a:r,:-!!iar

c,alilloyc.

iJIc

.,z-Lallcd

‘steiJ;d

ilrouced

:e,,ncrat,ve

~rtnrr~pa~,,~

.LIIuJ

irreversible.

Small white plaques have been observed to occasionally

persistinthe

ret:oconiBrnr!iva

spacefollowingsubconrunc!ival!herapv

Such plaquesappeartc haijeagra

-:il;;!il<jio,!!-

nature and.

aesthebrally displeasing. may necessitate su:gtcal removdl.

DIRECTIONS

USE: Do not use in ulcerative conditions of

the cornea (until a

negative

fluorescein

slain

has

been

obtained)

or

in

animals

with

Cushing’s

syndrome. Shake well

belore

use.

‘ntramuscular

m/ectcn

Oogs

Average dose

mgikg

(0.25

mLil0

Cats. Average dose 5 mg (0.125

mL)

Horses. 200 mg (5

vi,

/,

1;

Subiui,~u~,Z~rv'c2lry.

-7~

tiiy

p'io

tyc:

ulv~utu

418~~

:i;u;t6i;1b

oiudtu~~~.

MEAT WITHHOLDING PERIOD: DO

ADMINISTER TO HORSES LESS THAN 60

DAYS BEFORE SLAUGHTER FOR HUMAN CDNSUMPTIDN.

PRESENTATION:

Injection (multidose vial).

STORF

below

30°C

(Room

Temperature).

Protec?

from ltght

DISPOSE of contarner

wrapping with paper and placing in garbage.

Jurox Pty Ltd

Registered

Trade

Mark

Made

Australia by.

Pty. Ltd.

Unit 22, Slough Estate, Holker St.,

Srlverwater, NSW, 2128, AUSTRALIA

Licensed to Agvet Consultants Ltd.

70219

Hopetoun

Auckland.

PrescriptIon Ammal Remedy (P.A.R.) Class 1

Z RegIstered under the Animal Remedtes Act 1967 No 3633

404625

36216/01

18-1-2019

34 nieuwe maatschappelijke diensttijdprojecten van start

34 nieuwe maatschappelijke diensttijdprojecten van start

Vandaag hebben 34 nieuwe maatschappelijke diensttijdprojecten door heel Nederland bericht gekregen dat ze financiering krijgen en van start kunnen gaan. In de maatschappelijke diensttijd krijgen jongeren de mogelijkheid om hun eigen talenten te ontdekken en ontwikkelen tijdens een periode waarin ze zich vrijwillig inzetten voor een ander of voor de samenleving. Bij de nieuwe projecten kunnen jongeren hun talenten inzetten op terreinen als media, cultuur en musea, onderwijs, techniek en ICT, zorg en klima...

Netherlands - Ministerie van Volksgezondheid, Welzijn en Sport

11-1-2019

Health Canada safety review finds possible link between Fibristal and risk of liver injury

Health Canada safety review finds possible link between Fibristal and risk of liver injury

OTTAWA – Health Canada is informing Canadians that its safety review of Fibristal (ulipristal acetate) found a possible link between its use and the risk of a rare but serious liver injury.

Health Canada

30-10-2018

FDA takes action to stop the use of lead acetate in hair dyes

FDA takes action to stop the use of lead acetate in hair dyes

FDA takes action to stop the use of lead acetate in hair dyes. FDA will no longer allow lead acetate to be used in certain hair coloring products based on data that demonstrate that there is no longer a reasonable certainty of no harm from the use of this color additive.

FDA - U.S. Food and Drug Administration

10-8-2018

FDA approves new vaginal ring for one year of birth control

FDA approves new vaginal ring for one year of birth control

FDA approved Annovera (segesterone acetate and ethinyl estradiol vaginal system), a combined hormonal contraceptive for women of reproductive age used to prevent pregnancy and is the first vaginal ring contraceptive that can be used for an entire year.

FDA - U.S. Food and Drug Administration

29-5-2018

TAYTULLA (norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules) by Allergan: Recall - Due to Out of Sequence Capsules

TAYTULLA (norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules) by Allergan: Recall - Due to Out of Sequence Capsules

Allergan recently identified, through a physician report, that four placebo capsules were placed out of order in a sample pack of TAYTULLA. Specifically, the first four days of therapy had four non-hormonal placebo capsules instead of active capsules. As a result of this packaging error, oral contraceptive capsules, that are taken out of sequence, may place the user at risk for contraceptive failure and unintended pregnancy. The reversing of the order may not be apparent to either new users or previous ...

FDA - U.S. Food and Drug Administration

29-5-2018

Allergan Issues Nationwide Voluntary Recall of TAYTULLA® Softgel Capsules 1mg/20mcg Sample Packs Due to Out of Sequence Capsules

Allergan Issues Nationwide Voluntary Recall of TAYTULLA® Softgel Capsules 1mg/20mcg Sample Packs Due to Out of Sequence Capsules

Allergan plc (NYSE:AGN) today issued a voluntary recall in the US market of one lot (Lot# 5620706, Expiry May-2019) of TAYTULLA® (norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules) 1mg/20mcg, 6x28 physicians sample pack, indicated for use by women to prevent pregnancy. Allergan recently identified, through a physician report, that four placebo capsules were placed out of order in a sample pack of TAYTULLA. Specifically, the first four days of therapy had four non-hormonal...

FDA - U.S. Food and Drug Administration

15-3-2018

Health Canada to conduct review of a new potential safety risk of Fibristal (ulipristal acetate), a medication used to treat fibroids

Health Canada to conduct review of a new potential safety risk of Fibristal (ulipristal acetate), a medication used to treat fibroids

OTTAWA - Health Canada is advising Canadians that it will be conducting a safety review of Fibristal (ulipristal acetate), a medication used to treat uterine fibroids in women. Health Canada's review is a result of Canadian and European reports of serious adverse events affecting the liver.

Health Canada

20-12-2018


Orphan designation: 1-(3-methylbutanoyl)-L-aspartyl-L-threonyl-L-histidyl-L-phenylalanyl-L-prolyl-(L-cystinyl-L-isoleucyl-[(N6-(S)-4-carboxy-4-palmitamidobutanoyl)-L-lysinyl]-L-phenylalanyl-L-glutamyl-L-prolyl-L-arginyl-L-serinyl-L-lysinyl-L-glycinyl-L-c

Orphan designation: 1-(3-methylbutanoyl)-L-aspartyl-L-threonyl-L-histidyl-L-phenylalanyl-L-prolyl-(L-cystinyl-L-isoleucyl-[(N6-(S)-4-carboxy-4-palmitamidobutanoyl)-L-lysinyl]-L-phenylalanyl-L-glutamyl-L-prolyl-L-arginyl-L-serinyl-L-lysinyl-L-glycinyl-L-c

Orphan designation: 1-(3-methylbutanoyl)-L-aspartyl-L-threonyl-L-histidyl-L-phenylalanyl-L-prolyl-(L-cystinyl-L-isoleucyl-[(N6-(S)-4-carboxy-4-palmitamidobutanoyl)-L-lysinyl]-L-phenylalanyl-L-glutamyl-L-prolyl-L-arginyl-L-serinyl-L-lysinyl-L-glycinyl-L-cystinyl)-L-lysinamide, disulfide, acetate salt, Treatment of beta-thalassaemia intermedia and major, 24/08/2018, Positive

Europe - EMA - European Medicines Agency

18-12-2018


Orphan designation: H-Phe-Ser-Arg-Tyr-Ala-Arg-OH acetate (Alirinetide), Treatment of amyotrophic lateral sclerosis, 30/05/2016, Positive

Orphan designation: H-Phe-Ser-Arg-Tyr-Ala-Arg-OH acetate (Alirinetide), Treatment of amyotrophic lateral sclerosis, 30/05/2016, Positive

Orphan designation: H-Phe-Ser-Arg-Tyr-Ala-Arg-OH acetate (Alirinetide), Treatment of amyotrophic lateral sclerosis, 30/05/2016, Positive

Europe - EMA - European Medicines Agency

10-12-2018

EU/3/16/1662 (QRC Ireland)

EU/3/16/1662 (QRC Ireland)

EU/3/16/1662 (Active substance: H-Phe-Ser-Arg-Tyr-Ala-Arg-OH acetate) - Transfer of orphan designation - Commission Decision (2018)8626 of Mon, 10 Dec 2018 European Medicines Agency (EMA) procedure number: EMA/OD/011/16/T/01

Europe -DG Health and Food Safety

21-11-2018

Osurnia (Elanco GmbH)

Osurnia (Elanco GmbH)

Osurnia (Active substance: terbinafine / florfenicol / betamethasone acetate) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2018)7842 of Wed, 21 Nov 2018 European Medicines Agency (EMA) procedure number: EMEA/V/C/003753/T/0010

Europe -DG Health and Food Safety

21-11-2018

EU/3/18/2086 (Santhera Pharmaceuticals (Deutschland) GmbH)

EU/3/18/2086 (Santhera Pharmaceuticals (Deutschland) GmbH)

EU/3/18/2086 (Active substance: Cyclo[L-alanyl-L-seryl-L-isoleucyl-L-prolyl-L-prolyl-L-glutaminyl-L-lysyl-L-tyrosyl-D-prolyl-L-prolyl-(2S)-2-aminodecanoyl-L-alpha-glutamyl-L-threonyl]acetate) - Orphan designation - Commission Decision (2018)7795 of Wed, 21 Nov 2018 European Medicines Agency (EMA) procedure number: EMA/OD/106/18

Europe -DG Health and Food Safety

1-10-2018

EU/3/03/133 (Shire Orphan Therapies GmbH)

EU/3/03/133 (Shire Orphan Therapies GmbH)

EU/3/03/133 (Active substance: Icatibant acetate) - Transfer of orphan designation - Commission Decision (2018)6432 of Mon, 01 Oct 2018 European Medicines Agency (EMA) procedure number: EMA/OD/054/02/T/01

Europe -DG Health and Food Safety

29-8-2018

Ulipristal Acetate Gedeon Richter (Gedeon Richter Plc.)

Ulipristal Acetate Gedeon Richter (Gedeon Richter Plc.)

Ulipristal Acetate Gedeon Richter (Active substance: Ulipristal Acetate) - Centralised - Authorisation - Commission Decision (2018)5779 of Wed, 29 Aug 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/5017

Europe -DG Health and Food Safety

28-8-2018

EU/3/18/2058 (IQVIA RDS Ireland Limited)

EU/3/18/2058 (IQVIA RDS Ireland Limited)

EU/3/18/2058 (Active substance: 1-(3-methylbutanoyl)-L-aspartyl-L-threonyl-L-histidyl-L-phenylalanyl-L-prolyl-(L-cystinyl-L-isoleucyl-[(N6-(S)-4-carboxy-4-palmitamidobutanoyl)-L-lysinyl]-L-phenylalanyl-L-glutamyl-L-prolyl-L-arginyl-L-serinyl-L-lysinyl-L-glycinyl-L-cystinyl)-L-lysinamide, disulfide, acetate) - Orphan designation - Commission Decision (2018)5730 of Tue, 28 Aug 2018 European Medicines Agency (EMA) procedure number: EMA/OD/099/18

Europe -DG Health and Food Safety

6-8-2018

Cetrotide (Merck Europe B.V.)

Cetrotide (Merck Europe B.V.)

Cetrotide (Active substance: Cetrorelix (as acetate)) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2018)5373 of Mon, 06 Aug 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/233/T/67

Europe -DG Health and Food Safety

12-6-2018

EU/3/17/1834 (Santhera Pharmaceuticals (Deutschland) GmbH)

EU/3/17/1834 (Santhera Pharmaceuticals (Deutschland) GmbH)

EU/3/17/1834 (Active substance: Cyclo[L-alanyl-L-seryl-L-isoleucyl-L-prolyl-L-prolyl-L-glutaminyl-L-lysyl-L-tyrosyl-D-prolyl-L-prolyl-(2S)-2-aminodecanoyl-L-alpha-glutamyl-L-threonyl]acetate salt) - Transfer of orphan designation - Commission Decision (2018)3797 of Tue, 12 Jun 2018 European Medicines Agency (EMA) procedure number: EMA/OD/244/16/T/01

Europe -DG Health and Food Safety

12-6-2018

EU/3/13/1114 (Santhera Pharmaceuticals (Deutschland) GmbH)

EU/3/13/1114 (Santhera Pharmaceuticals (Deutschland) GmbH)

EU/3/13/1114 (Active substance: Cyclo[L-alanyl-L-seryl-L-isoleucyl-L-prolyl-L-prolyl-L-glutaminyl-L-lysyl-L-tyrosyl-D-prolyl-L-prolyl-(2S)-2-aminodecanoyl-L-alpha-glutamyl-L-threonyl] acetate salt) - Transfer of orphan designation - Commission Decision (2018)3798 of Tue, 12 Jun 2018 European Medicines Agency (EMA) procedure number: EMA/OD/166/12/T/01

Europe -DG Health and Food Safety

29-5-2018

Osurnia (Elanco Europe Ltd)

Osurnia (Elanco Europe Ltd)

Osurnia (Active substance: terbinafine / florfenicol / betamethasone acetate) - Centralised - Yearly update - Commission Decision (2018)3406 of Tue, 29 May 2018

Europe -DG Health and Food Safety

15-5-2018

Starlix (Novartis Europharm Limited)

Starlix (Novartis Europharm Limited)

Starlix (Active substance: nateglinide) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2018)3063 of Tue, 15 May 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/335/T/34

Europe -DG Health and Food Safety

14-5-2018

Girolan and its associated name Apralan

Girolan and its associated name Apralan

Girolan and its associated name Apralan (Active substance: Apramycin sulfate) - Community Referrals - Art 34 - Commission Decision (2018)2989 of Mon, 14 May 2018 European Medicines Agency (EMA) procedure number: EMEA/V/A/122

Europe -DG Health and Food Safety

17-4-2018

EU/3/11/945 (Mallinckrodt Pharmaceuticals Ireland Limited)

EU/3/11/945 (Mallinckrodt Pharmaceuticals Ireland Limited)

EU/3/11/945 (Active substance: Ornithine phenylacetate) - Transfer of orphan designation - Commission Decision (2018)2355 of Tue, 17 Apr 2018 European Medicines Agency (EMA) procedure number: EMA/OD/105/11/T/03

Europe -DG Health and Food Safety